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Calibration of CTS5 in Women With
Early Estrogen Receptor–Positive
Breast Cancer
Noordhoek et al1 have expressed interest in assessing
the validity of the Clinical Treatment Score post-5 years
(CTS5), but unfortunately we disagree that their data
reliably support their key conclusion that the CTS5
overestimates risk in high-risk patients with estrogen
receptor–positive breast cancer who remain free of
distant recurrence after 5 years of endocrine therapy.
The CTS5 online calculator has been accessed more
than 88,000 times and therefore seems to be widely
used in patient care. As such, it is important that risk
estimates that affect care should be as accurate as we
can make them. We pointed out in our original paper
that improvements in patient care may in fact have
led to the CTS5 not accurately estimating the risk in
contemporary patients.2 This is a concern with all prog-
nostic tools that depend on substantial follow-up for
their development and validation. We therefore agree
that further study of more contemporary populations
is an important objective but regret to conclude that
the work by Noordhoek et al1 cannot provide a reliable
improvement in calibration.
We developed the CTS5 as a prognostic tool to aid in
making the decision on whether to extend adjuvant
endocrine therapy beyond 5 years if a patient remained
free of distant recurrence (DR) at that time.2 It esti-
mates the risk of recurrence in the absence of ex-
tended therapy to allow decisions to be made on the
potential benefit from extending therapy. Development
and validation of this tool can be reliably conducted
only in patients who have not received such extended
therapy. The ATAC and BIG1-98 trials finished their
recruitment in 2000 and 2003, respectively.3,4 Given
that data first emerged on the benefits of endocrine
treatment beyond 5 years with the publication in late
2003 of the MA17 trial on the impact of letrozole
following 5 years of tamoxifen,5 we estimated that
, 1% and , 5% of patients, respectively, would have
received extended therapy. Noordhoek et al1 assessed
the CTS5 in the IDEAL and TEAM trials.6,7 In the former,
all patients received extended therapy. In the latter,
recruitment completed in 2006 and although the pro-
portion of patients receiving extended therapy in TEAM
was not known or estimated, it would undoubtedly be
greater than that in the ATAC and BIG1-98 populations.
Noordhoek et al1 note the possibility that the extension
of endocrine therapy in their studies may have led to
a slight reduction in late DR rates, reflecting that this
is unlikely to explain the 16% risk difference seen in
their analysis. This 16% difference appears to be that
seen between the observed versus the expected
number of events in the 10% of patients at the high-
est risk in the IDEAL trial and is therefore at the
very extreme of the high-risk population. Their data
in Table 2 and Figure 3B indicate that the difference in
risk between observed and expected distant recurrence
rates is largely proportional across the population;
our estimate from this is that the relative difference
is approximately 40% in the IDEAL trial. Such a pro-
portional effect is consistent with all the patients in
IDEAL receiving extended therapy irrespective of risk.
It is also notable that 70% of the IDEAL patients had
received 2.5 or 5 years of tamoxifen before the ran-
dom assignment to an aromatase inhibitor at 5 years.
The MA17 study reported a hazard ratio for disease-
free survival of 0.57 (95% CI, 0.43 to 0.75), that is,
an estimated 43% reduction, for patients receiving
letrozole after 5 years of tamoxifen.5
Although the IDEAL study showed proportional re-
ductions in observed versus predicted risk in all risk
categories, the TEAM study found this in only the high-
risk patients, where the relative reduction of observed
versus expected events was approximately 25%. This
high-risk group is likely to be the most affected by
clinicians recommending extended therapy to patients
on the basis of a conventional consideration of the
clinicopathologic factors that constitute the CTS5.
Although concerned that we differ in the interpreta-
tion of the report by Noordhoek et al,1 we agree that
accurate estimates of risk are important across the
risk spectrum. We are reassured that their report af-
fects only those patients predicted to be above the
intermediate–high risk cutoff, and these are the ones
who would be strong candidates for extended endo-
crine therapy irrespective of their absolute risk estimate.
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